GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Equity-to-Asset

Surrozen (Surrozen) Equity-to-Asset : 0.82 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Surrozen Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Surrozen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $37.94 Mil. Surrozen's Total Assets for the quarter that ended in Dec. 2023 was $46.08 Mil.

The historical rank and industry rank for Surrozen's Equity-to-Asset or its related term are showing as below:

SRZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.76   Med: 0.81   Max: 0.85
Current: 0.82

During the past 4 years, the highest Equity to Asset Ratio of Surrozen was 0.85. The lowest was 0.76. And the median was 0.81.

SRZN's Equity-to-Asset is ranked better than
70.89% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs SRZN: 0.82

Surrozen Equity-to-Asset Historical Data

The historical data trend for Surrozen's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Equity-to-Asset Chart

Surrozen Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.76 0.80 0.85 0.82

Surrozen Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.85 0.86 0.84 0.82

Competitive Comparison of Surrozen's Equity-to-Asset

For the Biotechnology subindustry, Surrozen's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surrozen's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Surrozen's Equity-to-Asset falls into.



Surrozen Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Surrozen's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=37.935/46.08
=

Surrozen's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=37.935/46.08
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surrozen  (NAS:SRZN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Surrozen Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Surrozen's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Surrozen (Surrozen) Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).
Executives
Yang Li officer: Exec. Vice President, Research C/O SURROZEN, INC., 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Anna Berkenblit director 830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md director, 10 percent owner 1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai director 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh officer: Chief Scientific Officer 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory other: Former VP Business Development C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove officer: Chief Medical Officer 1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Charles O Williams officer: Chief Financial Officer C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel other: Former Director 4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse director 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158